Business Insider3y
First non-Japanese CEO of Takeda has set out 2 objectives: to be an R&D-driven firm and to build global scale
When Christophe Weber was appointed CEO of Takeda in 2014, he set out on a mission to transform the 240-year old Japanese pharmaceutical company into a major global player. Over the past six years ...
FiercePharma16d
JPM25: Takeda spotlights 6 pipeline assets that could pull down up to $20B in collective peak sales
Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in ...
Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transition
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Management View Christophe Weber, CEO, announced his retirement ...
Axios on MSN3d
Embracing AI is necessary for legacy industries, leaders say
A commitment to embracing AI and the changing digital world are key to success in legacy industries, Bank of America CEO Brian Moynihan and Takeda Pharmaceutical CEO Christophe Weber said. Why it ...
FiercePharma20h
Fierce Pharma Asia—Takeda's next CEO; Enhertu's novel FDA nod; East Asian American C-suite execs
Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...